Overview

Study to Evaluate the Preliminary Safety, Efficacy, PK and PD of Bryostatin 1 in Patients With Alzheimer's Disease

Status:
Terminated
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
This study is being done to evaluate the safety, tolerability and potential effectiveness of a new investigational drug, bryostatin 1, in patients with Alzheimer's disease (AD).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Neurotrope Bioscience, Inc.
Collaborator:
Blanchette Rockefeller Neurosciences Insitute
Treatments:
Bryostatin 1